182 related articles for article (PubMed ID: 30703597)
1. Low Transforming Growth Factor-β3 Expression Predicts Tumor Malignancy in Meningiomas.
Ma J; Li D; Chen Y; Zhang Y; Song L; Tian K; Yang Y; Chen L; Weng J; Cao X; Hao S; Wang L; Wu Z; Zhang J
World Neurosurg; 2019 May; 125():e353-e360. PubMed ID: 30703597
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors, Survival, and Treatment for Intracranial World Health Organization Grade II Chordoid Meningiomas and Clear-Cell Meningiomas.
Zhang GJ; Zhang YS; Zhang GB; Yan XJ; Li CB; Zhang LW; Li D; Wu Z; Zhang JT
World Neurosurg; 2018 Sep; 117():e57-e66. PubMed ID: 29859361
[TBL] [Abstract][Full Text] [Related]
3. Long-term surgical outcome and biological prognostic factors in patients with skull base meningiomas.
Ohba S; Kobayashi M; Horiguchi T; Onozuka S; Yoshida K; Ohira T; Kawase T
J Neurosurg; 2011 May; 114(5):1278-87. PubMed ID: 21166572
[TBL] [Abstract][Full Text] [Related]
4. Evolution and future of skull base surgery: the paradigm of skull base meningiomas.
Di Maio S; Ramanathan D; Garcia-Lopez R; Rocha MH; Guerrero FP; Ferreira M; Sekhar LN
World Neurosurg; 2012; 78(3-4):260-75. PubMed ID: 22120278
[TBL] [Abstract][Full Text] [Related]
5. Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute.
Weber DC; Schneider R; Goitein G; Koch T; Ares C; Geismar JH; Schertler A; Bolsi A; Hug EB
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):865-71. PubMed ID: 22138457
[TBL] [Abstract][Full Text] [Related]
6. The role of radiotherapy following gross-total resection of atypical meningiomas.
Komotar RJ; Iorgulescu JB; Raper DM; Holland EC; Beal K; Bilsky MH; Brennan CW; Tabar V; Sherman JH; Yamada Y; Gutin PH
J Neurosurg; 2012 Oct; 117(4):679-86. PubMed ID: 22920955
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning.
El Shafie RA; Czech M; Kessel KA; Habermehl D; Weber D; Rieken S; Bougatf N; Jäkel O; Debus J; Combs SE
Radiat Oncol; 2018 Mar; 13(1):54. PubMed ID: 29587795
[TBL] [Abstract][Full Text] [Related]
8. Progression-Free Survival and Factors Associated with Postoperative Recurrence in 126 Patients with Atypical Intracranial Meningioma.
Phonwijit L; Khawprapa C; Sitthinamsuwan B
World Neurosurg; 2017 Nov; 107():698-705. PubMed ID: 28838877
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic radiosurgery and stereotactic radiotherapy in the treatment of skull base meningiomas.
McGregor JM; Sarkar A
Otolaryngol Clin North Am; 2009 Aug; 42(4):677-88. PubMed ID: 19751872
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment.
Hammouche S; Clark S; Wong AH; Eldridge P; Farah JO
Acta Neurochir (Wien); 2014 Aug; 156(8):1475-81. PubMed ID: 24965072
[TBL] [Abstract][Full Text] [Related]
11. World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment.
Liu X; Shan B; Wang M; Xu J
World Neurosurg; 2018 Jan; 109():e352-e362. PubMed ID: 28987849
[TBL] [Abstract][Full Text] [Related]
12. Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma.
Park S; Cha YJ; Suh SH; Lee IJ; Lee KS; Hong CK; Kim JW
J Cancer Res Clin Oncol; 2019 May; 145(5):1351-1360. PubMed ID: 30953136
[TBL] [Abstract][Full Text] [Related]
13. Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature.
Savardekar AR; Patra DP; Bir S; Thakur JD; Mohammed N; Bollam P; Georgescu MM; Nanda A
World Neurosurg; 2018 Apr; 112():e74-e83. PubMed ID: 29258946
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.
Wang XQ; Jiang CC; Zhao L; Gong Y; Hu J; Chen H
J Neurosurg Pediatr; 2012 Nov; 10(5):423-33. PubMed ID: 22938082
[TBL] [Abstract][Full Text] [Related]
15. Low Expression of Phosphatase and Tensin Homolog and High Expression of Ki-67 as Risk Factors of Prognosis in Cranial Meningiomas.
Ma J; Zhang Y; Chen L; Chen Y; Yang Y; Li D; Wang L; Zhang J; Wu Z
World Neurosurg; 2020 Apr; 136():e196-e203. PubMed ID: 31887465
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy for atypical meningiomas.
Mair R; Morris K; Scott I; Carroll TA
J Neurosurg; 2011 Oct; 115(4):811-9. PubMed ID: 21699480
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
18. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management.
Gousias K; Schramm J; Simon M
J Neurosurg; 2016 Sep; 125(3):551-60. PubMed ID: 26824369
[TBL] [Abstract][Full Text] [Related]
19. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
[TBL] [Abstract][Full Text] [Related]
20. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
McGovern SL; Aldape KD; Munsell MF; Mahajan A; DeMonte F; Woo SY
J Neurosurg; 2010 May; 112(5):925-33. PubMed ID: 19799498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
